Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96,516 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
Yang P, Cai QQ, Zhang W, Liu SZ, Liu H, Sun XH, Dong YJ, Xiao XB, Wang JW, Li ZL, Huang WR, Li LH, Bao HZ, Yang W, Wang YL, Wang SY, He J, Li XL, Liu AC, Jing HM. Yang P, et al. Among authors: liu ac, liu h, liu sz. Cancer Med. 2023 Jun;12(12):13204-13216. doi: 10.1002/cam4.6009. Epub 2023 May 6. Cancer Med. 2023. PMID: 37148540 Free PMC article.
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.
Bachy E, Savage KJ, Huang H, Kwong YL, Gritti G, Zhang Q, Liberati AM, Cao J, Yang H, Hao S, Hu J, Zhou K, Petrini M, Russo F, Zhang H, Sang W, Ji J, Ferreri AJM, Damaj GL, Liu H, Zhang W, Ke X, Ghiggi C, Huang S, Li X, Yao H, Paik J, Novotny W, Zhou W, Zhu H, Zinzani PL. Bachy E, et al. Among authors: liu h. Blood Adv. 2023 Aug 22;7(16):4435-4447. doi: 10.1182/bloodadvances.2022009575. Blood Adv. 2023. PMID: 37276067 Free PMC article. Clinical Trial.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: liu y, liu h. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph+ acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.
Liu H, Xu H, Chi P, Feng Z, Xu X, Nie D, Li X, Liang X, Fan Z, Xu N, Huang F, Lin R, Wang Z, Jin H, Zhou H, Guo X, Lin D, Sun J, Liu Q, Xuan L. Liu H, et al. Among authors: liu q. Am J Hematol. 2025 Jan;100(1):33-37. doi: 10.1002/ajh.27516. Epub 2024 Nov 16. Am J Hematol. 2025. PMID: 39548804
Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study.
Zou QH, Liu H, Huang CW, Kang LP, Qiu B, Mai JL, Lin YB, Liang Y. Zou QH, et al. Among authors: liu h. Transl Lung Cancer Res. 2023 Jan 31;12(1):96-108. doi: 10.21037/tlcr-22-256. Epub 2023 Jan 16. Transl Lung Cancer Res. 2023. PMID: 36762055 Free PMC article.
96,516 results
You have reached the last available page of results. Please see the User Guide for more information.